Genelux Corporation · NASDAQ:GNLX
Genelux — Investor Presentation (October 2023)
38 slides from Genelux's investor presentation, Oct 10, 2023
Slide 1: Redefining Immuno-Oncology
Redefining Immuno-Oncology Corporate Presentation | October 2023
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections, about Ge
Slide 3: Highlights
Highlights Olvi-Vec: De-risked late-stage Clinical Program Ongoing pivotal trial in late-stage Ovarian Cancer, SCLC and planned Phase 2 trial Adjuvant Maintenance NSCLC CHOICE™ Platform; Broad and Diverse Discovery Engine Library with over 500 novel vaccinia strains and 110+ transgenes Validating St
Slide 4: The Most Advanced Non-local Delivery Oncolytic Immunotherapy
The Most Advanced Non-local Delivery Oncolytic Immunotherapy Olvi-Vec: Engineered to selectively target and eliminate tumor cells while inducing a robust patient-specific immune response Physician-preferred Routes Antitumor Effect Ideal Backbone of of Delivery and Well Tolerated Combination Therapy
Slide 5: Diversified Designs and Indications Exploit Competitive Advantages
Diversified Designs and Indications Exploit Competitive Advantages Olvi-Vec Human Health Design _Preclinical Phase 1 Phase 2 Phase 3 Collaborators Ovarian Cancer {plotinum-resistont/cefcactory) Regional Route Gunchecy, Ph3 OnPrime/GOG-3076 Study Actively Enrolling GOG: (Cooperative Group) ‘Non-Small
Slide 6: Selective Replication In Tumors Unleashes Immune System Against Cancer
Selective Re lication In Tumors Unleashes Immune System Against Cancer Key Takeaways Olvi-Vec is g robust immune modulator that utilizes a triple mode of action to mount a personalized attack against cancer cells Hi iroughout the body * Kills cancer cells directly + Enhances (neo)antigen presen anon
Slide 7: Olvi-Vec-Primed Immunochemotherapy: Overcoming Drug Resistance
Olvi-Vec-Primed Immunochemotherapy: Overcoming Drug Resistance Olvi-Vec-Induced Hot Tumor Pro-therapeutic gene expression ; P emotherapy synergy > Positive regulation of T-cell activating inog=ric call death and trafficking ee i : i Depletion of suppressor cells > Expression profiles correlated to b
Slide 8: Over $4 Billion in Transactions in Active Oncolytic Space
Over $4 Billion in Transactions in Active Oncolytic Space Cs 2237S With its recent IPO, Genelux joined the public markets as a Phase 3 company pO Replimune’ Replimune completed a $225 milion offering as well as $200M in non-dilutive debt financing ‘A maturing field with Amgen launching Imiygie in 20
Slide 9: Competitive Advantages of Olvi-Vec as an Oncolytic Virus
Competi ive Advantages of Olvi-Vec as an Oncolytic Virus Key Takeaways UN Oncolytic Virus Space Olvi-Vec Key Advantages: Key Players and Assets Olvi-Vec Key Advantages * Broad spectrum of activity Genecurx> Olvi-vec + Tumor selectivity @ Target & Treat Metastatic Disease ee AMGEN Herpes é eure activ
Slide 10: Creating a New Paradigm Of Oncolytic Virus Drug Development
Creating a New Paradigm Of Oncolytic Virus Drug Development 7 completed clinical trials ~150 patients @enNevcux Our Advantage Systemic Dosing _Robust Immune and Redosing Activation Profile Target & Treat Metastatic Diseases Broad spectrum of accessible tumor types AMGEN {!} Replimune® ilere] T-VEC (
Slide 11: Phase 1b: Anti-tumor Activity as Monotherapy Leading into Combination
hase 1b: Anti-tumor Activity as Monotherapy Leading into Combination Key Clinical Takeaways IN + mPFS of 6.1 months median 4 prior lines; 5%Cl: 2.2-NA) for the six patients in Cohort 1 virus monotherapy - the dose used in Ph2- + SOC-AURELIA regimen (1-2 prior lines; mPFS: 6.7 mos) + ELAHARE (1-3 pri
Slide 12: Completed Phase 2 Tested Olvi-Vec Immunochemotherapy
Completed Phase 2 Tested Olvi-Vec Immunochemothera Olvi-Vec Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer Data Presentations Reveucicreena 7) puaioulsnaaGon aan Sater Det Antal eetne cesta n=27 Gynecologic Cancer Society Oral P
Slide 13: Key Clinical Takeaways
Key Clinical Takeaways Promising ORR and PFS, and clinical reversal of platinum resistance and refractoriness among patients with PRROC + All patients had documented progressive disease at enrollment * Overall response rate in 27 patients was 54% with 7.6- month median duration of response * Histori
Slide 14: Demonstrated Deep and Durable Tumor Shrinkage
Demonstrated Deep and Durable Tumor Shrinkage Key Clinical Takeaways Refractory patients performed as well as resistant patients Tumor Shrinkage * Overall, 86% of PRROC patients showed tumor reduction, with 91% of Platinum-refractory patients showing tumor reduction + Four patients had 100% reductio
Slide 15: Olvi-Vec-Primed Immunochemotherapy Overcomes “Refractoriness”
Olvi-Vec-Primed Immunochemotherapy Overcomes “Refractoriness” Exemplary platinum-refractory patients, after platinum re-challenge, achieved PFS exceeding any prior lines 15B-01; ‘Stage IIIB papillary serous ECOG: 0 BRCA negative PD-Li negative Stage Il grade serous ECOG: 0 BRCA negative PD-L1 negati
Slide 16: Durable Benefit of Overall Survival via Clinically-Validated Endpoint
Durable Benefit of Overall Survival via Clinically-Validated Endpoint Key Clinical Takeaways IN 20% long-term survivors consistent with commercially successful immunotherapies + Historical data in 4th line and beyond shows a median overall survival of only 9.8 months » Onamedian Sth line of treatmen
Slide 17: “Allcomers” Approach May Reset Life Clock of Heavily Pre-treated Patients
“Allcomers” Approach May Reset Life Clock of Heavily Pre-treated Patients Key Trial Takeaways IN Olvi-Vec addresses a broad and underserved pool of patients * Olvi-Vec trial inclusion criteria allows patients regardless of i) tumor biomarkers, ii) platinum refractory tumors, or (iii) number of prior
Slide 18: Phase 3 Pivotal Trial Design Founded on Phase 2 Trial Design & Results
Phase 3 Pivotal Trial Design Founded on Phase 2 Trial Design & Results Trial design intends to replicate previous data showing anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the tumor microenvironment Key Inclusion Criteri Multi-center, randomized open-label 86 + High-grade s
Slide 19: Systemic administration demonstrated dose-dependent OS benefit
Systemic administration demonstrated dose-dependent OS benefit IN Key Trial Takeaways Demonstrated feasibility and clinical benefit of multiple lv cycles * Median 5 prior lines of therapy * Regimen: various dosing levels and schedules iret over 4-6 months, + Well tolerated: noMTD reached with one DL
Slide 20: Systemic Administration + Chemo Generated Encouraging Data
tration + Chemo Generated Encouraging Data Systemic Admi N adverttath | eeuane ° Expanded Access Program Key Trial Takeaways Recurrent metastatic cervical cancer | High-grade pancreatic cancer with lung mets lung & liver mets Anti-tumor effect of IV ‘Case Report (Pt 8214-06) Report (PLAZIA-O4) Immun
Slide 21: Genelux has Partnered with Newsoara BioPharma Co., Ltd
Genelux has Partnered with Newsoara BioPharma Co., Ltd NEWSGARA HIGHLIGHTS 7 5 ENELUX NEWSGARA GREhER Pipelines Phase IIb/III Indications Phase II $850 Million Valuation Top 10 Blue-chip Biotech Investors 2023 Benny Li, PhD Founder and Chief Executive Officer 20+ yrs. global and China local pharma F
Slide 22: Validating Industry Collaboration with Newsoara BioPharma Co., Ltd
Validating Industry Collaboration with Newsoara BioPharma Co,, Ltd Key Takeaways IN > Newsoara will fund the US-based Genelux Phase 2 trial in NSCLC. - Newsoara has development and commercialization rights in Greater China + Interim readout for one or more systemic administration trials expected as
Slide 23: V2ACT Therapeutics LLC: Joint Venture between GNLX and TVAX BioMedical
V2ACT Therapeutics LLC: Joint Venture between GNLX and TVAX BioMedical Key Trial Takeaways iN V2ACT Therapeutics is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. established to develop and test V2ACT. V2ACT Immunothera| Vaccination increases the numbers of neoantigen-specific
Slide 24: Estimated Billion Dollar Plus annual Olvi-Vec Commercial Opportunity (US)
Estimated Billion Dollar Plus annual Olvi-Vec Commercial Opportunity (us) Ovarian Cancer Market? Ovarian Cancer ee q Non-Small Cell Lung Cancer ‘$1.8B jn 2022, expected CAG Additional revenue drivers: eo © > Re-treatment > Front-Line therapy > Additional Indications, i.e.: ~236,511 women in the US c
Slide 25: Integrated R&D and Manufacturing Capabilities For Phase 3 And Launch
Integrated R&D and Manufacturing Capabilities For Phase 3 And Launch Large-Scale cGMP Manufacturing _— iN Process to Optimize Production ‘ey Takeaways Headquarters ‘wanifacturnic Foal Westlake Village, CA, USA D; + Established and equipped an al ‘cS wage. Geta orpchy Pa conti folied 7) Kir Manufactu
Slide 26: Commercial Strategy
Commercial Strategy Partnerships Self-Manufacturing Patients Reimbursement Leverage partnership Large-Scale cGMP Population without Compelling Value with GOG Foundation Manufacturing Standard of Care Proposition for Payors + Preeminent US-based * Control of Production + PRROC patients lack ° Sipiffe
Slide 27: CHOICE Platform Library: 500+ Vectors with 110+ Transgenes
Choice Platform Library: 500+ Vectors with 110+ Transgenes Engineered and selected clonal isolated (non-GMO) viral strains identified from in vitro and in vivo selection criteria Virus-encoded transgenes Therapeutic Well Growth & Differentiation Regulators Hormones Genes Metastasis Suppressor Genes
Slide 28: Intellectual Property: Market Exclusivity & Freedom to Operate
Intellectual Property: Market Exclusivity & Freedom to Operate Patent Portfolio: 33 issued patents; 7 pending Olvi-Vec covered by Composition of Matter (2031) and Manufacturing (2038) St ng IP = Olvi-Vec: Worldwide operating freedom; Regulatory No third-party royalties due Designations Long Duration
Slide 29: Accomplished Leadership Team
Accomplished Leadership Team j Board of Directors Executive Team THOMAS ZINDRICK, JD agen acvamnics Chairman of the Board — Writ vers Squats JAMES L. TYREE, MBA e Lead independent Sector Thee anes Thomas Zindrick, JD Lourie Zak Paul Scigalla, MD, PhD Sean Ryder, JD MARY MIRABELLI, MBA cant Chief Exe
Slide 30: Genelux Has Executed on Multiple Milestones and is Positioned for the Future
Genelux Has Executed on Multiple Milestones and is Positioned for the Future Executed Milestones IN Executed on go public strategy i) and follow on with $60M raised oO Initiation of Phase 3 Trial in oO PRROC , Phase 2 results published in JAMA Oncology r) Collaboration and License agreement with New
Slide 31: Expected Operating Runway into 1Q 2026
Expected Operating Runway into 1Q 2026 Capitalization Summary Analyst Coverage Stock Symbol GNLX Bruce Jackson M.S,, MBA Share Price!) $28.89 * Kemp Dolliver CFA Shares Outstanding 25.98M res Outstanding * Jason McCarthy, Ph.D. Market Capitalization $750M Cash & Equivalents”) $28.40M aiken pot ca Ma
Slide 32: Highlights
Highlights Olvi-Vec: De-risked late-stage Clinical Program Ongoing pivotal trial in late-stage Ovarian Cancer, SCLC and planned Phase 2 trial Adjuvant Maintenance NSCLC CHOICE™ Platform; Broad and Diverse Discovery Engine Library with over 500 novel vaccinia strains and 110+ transgenes 7 Validating
Slide 33: Appendix
HeNELUXx Redefining Immuno-Oncology Corporate Presentation | October 2023 Appendix
Slide 34: Accomplished Clinical Advisory Board
Accom lished Clinical Advisory Board Robert Holloway, MD CHAIRMAN Cie aca cio arian ae Robert Coleman, MD Member Albert A. Mendivil, MD Member Deputy oer of hs Univers of Thomas J. Herzog. MD Cineiesicaenr| Toate Chief Executive Officer Protersorand olsen orector, rivers comprehensive ‘Caneet Costar
Slide 35: Olvi-Vec Demonstrates Monotherapy Oncolysis and Immune Activation
Olvi-Vec Demonstrates Monotherapy Oncolysis and Immune Activation (VIRO-15: monotherapy) Key Takeaways iN (PL#15A01) (PLAS A-11) Elimination of Cancer Cells after Increased Lymphocyte infiltrationin different cavities Olvi-Vec monotherapy shows decreased tumor cells and increase immune activation pe
Slide 36: CD8+ T-cells: Infiltrating Lymphocytes are Prognostic for Response/Survival
CD8+ T-cells: infiltrating Lymphocytes are Prognostic for Response/Survival Pt# 15A-16 Pt# 15A-18 Pt# 45A-23 —_ Pan] ae BSc Se eae cos+ co4+ cD8+ co4+ cose 7 rostolw-vec (prior to subsequent chemotherapy) Endogenous TiLs (intrar tumoral and stromal) are very low in ovarian cancer Pti 15A-16 Ptit 15A
Slide 37: VIRO-15: Monotherapy
(MRO-15: manatherapy} Tanta tamorantigen presentation Long-lasting, Tumor-specific T cell response corresponds to tumor reduction IN Off-the-Shelf Personalized Medicine: Single Agent generates Individualized Results Key Takeaways * Olvi-Vec induces favorable & long-lasting Tumor-specific T-cell Resp
Slide 38: Olvi-Vec: Ideal Backbone for Combination Therapy
Olvi-Vec: Ideal Backbone for Combination Thera Converts Tumor Microenvironment to Inflammatory “Hot Spot” NCT01443260/TUE Study 6 zg es Induction of acute inflammatory 3 i, cytokines 5, (ThI-type related) ra 52) VIRO-I5 Study 31 zy Baseline Massive inflammatory response after cycle 1 of vieus treatm